Biotech Conagen Acquires Production Platform of Therapeutic Proteins

Food and Healthcare Press Releases Thursday August 22, 2019 12:45
BEDFORD, Massachusetts--22 Aug--PRNewswire/InfoQuest
The technology should reduce costs to patients and accelerate drug development

Conagen, a vertically integrated synthetic biology company located in Boston's biotech corridor, announced today that it has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins.

The acquisition includes several patents covering the platform and all associated tangible assets, establishing Conagen as a leading developer of active pharmaceutical ingredients.
In addition to a suite of more than 10 already developed therapeutic glycoproteins, the host platform will be used by Conagen for development of both novel and generic drugs.

Industrial fermentation typically employs microbes which can be cultured rapidly at the largest scales without cell disruption or losses in productivity. Characteristics of these therapeutics, which include desirable glycostructures and other post-translational modifications, have limited their commercial production to fragile mammalian cell systems at relatively small scales.

"One of the most exciting features of this host organism is its ability to express glycoproteins harboring glycostructures which promote the desired immune cell functions. This is a very unusual feature to find in a robustly fermentable microbe. It is also advantaged by its ability to tolerate the engineering required to customize these glycostructures while preserving the microbe's robustness," said Vice President of Research and Development, Casey Lippmeier

The platform will reduce costs, and the savings can be passed down to patients. This is important to the pharmaceutical industry which is under increasing pressure to reduce time and capital in developing drugs," said Oliver Yu, Ph.D., co-founder, and CEO of Conagen.

The largest category of therapeutic glycoproteins is the blockbuster monoclonal antibodies upon which the entire $100 billion immunotherapy and antibody-drug conjugate market is based.
More about Conagen: Making Impossible Possible(R)

Conagen is a leader in bioengineering. The company's scientists and engineers use the latest synthetic biology tools to design metabolic pathways, improve production organisms, and optimize production procedures. It focuses on bioproduction of high-value ingredients for food, nutrition, flavor and fragrance, pharmaceutical, and renewable materials industries. For more information, visit the official company website at www.conagen-inc.com

Logo - https://mma.prnewswire.com/media/959473/Conagen_Logo.jpg

Latest Press Release

Califia Farms Completes Landmark $225 Million Financing with Diverse Group of Global Investors

Funding Provides Califia Farms, a leading plant-based food and beverage company, with long-term capital and global support for continued rapid expansion, and disruption of the $1 trillion+ dairy and ready-to-drink coffee markets Califia Farms(R), a...

Herbalife Nutrition Expert Shares Valuable Nutrition Tips to Make Smart Food Choices and Promote Healthy Eating Habits

Herbalife Nutrition (NYSE:HLF), a premier global nutrition company, recently invited Dr.Jonathan Yarom, Herbalife Nutrition Advisory Board Member, to share valuable health and nutrition information to its Independent Members in Thailand. Dr. Yarom has...

Jetts 24 Hour Fitness registers record-breaking growth in Asian fitness industry with opening of 22 clubs across Thailand in 24 months

Jetts 24 Hour Fitness, the fastest-growing fitness chain in Thailand, now has a total of 22 clubs up and running in the country in a testament to its philosophy of bringing exercise opportunities to people with the utmost ease of convenience. Thailand's...

12th Consecutive Year Leading United States in Organ Donation for Gift of Life Donor Program

Region Again Breaks Two U.S. Records, Showing Extraordinary Generosity and Clinical Leadership: Most Organ Donors and Life-Saving Transplants For the 12th consecutive year, Gift of Life Donor Program is the nation's leading organ procurement...

CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs

CF PharmTech, Inc., a pharmaceutical company with a vision to provide quality and affordable respiratory drug products globally, announced it has raised a $90 million Series E investment led by New Alliance Capital. The investment included participation...

Related Topics